Abstract
The development of biologics targeting various aspects of type 2 inflammation for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) will provide clinicians with powerful tools to help treat these patients. However, other therapies are also available, and positioning of biologics in a management algorithm will require comparative trials. In November 2019, the National Institute of Allergy and Infectious Diseases convened a workshop to consider potential future trial designs. Workshop participants represented a wide spectrum of clinical specialties, including otolaryngology, allergy, and pulmonary medicine, as well as expertise in CRSwNP pathophysiology and in trial methodology and statistics. The workshop discussed the current state of knowledge in CRSwNP and considered the advantages and disadvantages of various clinical trial or observational study designs and various clinical outcomes. The output from this workshop, which is presented in this report, will hopefully provide investigators with adequate information and ideas to design future studies and answer critical clinical questions. It will also help clinicians understand the current state of the management of CRSwNP and its gaps and be more able to interpret the new information to come.
Original language | English (US) |
---|---|
Pages (from-to) | 1532-1549.e1 |
Journal | Journal of Allergy and Clinical Immunology: In Practice |
Volume | 8 |
Issue number | 5 |
DOIs | |
State | Published - May 2020 |
Keywords
- Clinical trials
- Dupilumab
- Mepolizumab
- Nasal polyposis
- Omalizumab
- Outcomes
- Rhinosinusitis
- Type 2 inflammation
ASJC Scopus subject areas
- Immunology and Allergy